Inizio launches Intelligent Congress: Turning medical event investment into measurable impact
May 12, 2026 | Congress, Pharma, healthcare
Inizio, the global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress – a connected, end-to-end solution designed to help pharma organizations maximize the value of congress investment and deliver measurable business impact.
Medical congresses remain one of the most critical data milestones in an asset’s development, providing valuable opportunities to translate scientific innovation into clinical practice. However, many organizations still approach congresses as standalone events, with fragmented planning across therapy area teams, limited alignment to overarching disease area objectives, and limited clarity on measuring success beyond immediate metrics.
By operating as a single, integrated partner across the full data and congress lifecycle, Inizio helps clients navigate complexity, align stakeholders, and gain clearer confidence in the impact of their congress investments. Our strength lies in an unmatched vantage point – combining deep, cross-functional expertise with end-to-end visibility across the product lifecycle.
Intelligent Congress is built on this foundation. Drawing on more than 30 years of experience across therapy areas, it unites strategy, experience design, delivery, and measurement into one cohesive model. This depth and breadth enable clients to move beyond fragmented, activity-based metrics and instead focus on what truly matters – meaningful shifts in HCP understanding, engagement, and behavior.
Discover how Intelligent Congress can help you create more strategic, measurable, and impactful HCP engagement. Visit our congress page or connect with the Inizio team at booth 21157 during the ASCO® Annual Meeting 2026 to see Intelligent Congress in action.
Read full article here.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Research Partnership launches new patient Living with Atopic Dermatitis (US) 2017 report
Living with Atopic Dermatitis (AD) is a study conducted amongst 100 adults and 50 caregivers in the US. The report will consist of 45-minute quantitative and 30-minute qualitative interviews with AD…
The value of design thinking: Incorporating creative and graphic design into pharma market research
How do we keep research design fresh and interesting? How do we ensure that we’re inspiring our respondents to give us enlightening new insights, and encourage new ways of thinking?There…
Research Partnership launches new patient Living with Psoriasis 2017 (EU) report
Living with Psoriasis is a study conducted amongst 615 patients in Europe. The report will consist of 30-minute online interviews with 600 patients and 15 qualitative interviews. It can be purchased…
Deep Dive – MINT: opportunities in ‘frontier’ markets?
According to British economist Jim O’Neill, MINT is the new BRIC. What is MINT? An acronym he coined for the ‘frontier’ markets of Mexico, Indonesia, Nigeria and Turkey. These are…
Webcast: Going for growth – Maximising your return on insights in Emerging Markets
Healthcare market research in emerging markets is still evolving, so finding the insights you require and then maximising the return on those insights can be challenging. Healthcare market research in emerging…
20 questions: Round 6
As it’s our 20th year anniversary, we invited our employees to play our version of 20 questions – this month we asked our employees about office life in Singapore.Watch the video: https://www.researchpartnership.com/news/2017/09/20-questions-round-6/
Ageing Asia: What does this mean for the future of healthcare?
Over the last 30 years, Asia’s economic growth has resulted in improved education and healthcare across a broad base of the population. This has contributed to declining fertility and increasing…
Punching above your weight: Combining behavioural and attitudinal data to strengthen segmentations
Segmentation solutions in healthcare are experiencing a welcome comeback. But there appear to be two camps emerging – one camp are proponents of the ‘behavioural’ segmentation based on secondary sales,…
Qualitative segmentation validation study with backroom brainstorm exercises
Our client had an oncology product in development for the treatment of prostate cancer. The company wanted to conduct research to inform future planning, list development, advisory board creation, and…
PMRC EU, Düsseldorf 2017
We are delighted to be exhibiting and presenting a paper at the Pharmaceutical Market Research Conference 24-25 October in Düsseldorf, GermanyDirector, Anne Cunningham, and Associate Director, Nicky Barclay-Prout, are representing…